Efficacy and Safety of Topiroxostat in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis

Jun Shen and Jia Sun

Background and Objective: Hyperuricemia (HUA) and chronic renal disease occurrences have both been sharply increasing in recent years, which have seriously affected public health. This meta-analysis compares topiroxostat in patients with chronic kidney disease and hyperuricemia. Materials and Methods: The machine searches eight databases to find studies on topiroxostat’s impact on individuals with chronic renal disease and HUA, both domestically and overseas. Utilising RevMan 5.3 software, data analysis was carried out following a thorough assessment of the quality of the literature. Results: A total of seven articles were included in this meta-analysis. All of them were thought of as controlled experiments. The test category’s uric acid levels significantly changed from the control group (SMD: -2.12; 95% Cl: -2.68, -1.56; p<0.01), as per 4 studies. The Estimated Glomerular Filtration Rate (eGFR) (SMD: 0.62; 95% Cl: -3.98, 5.23; p = 0.790), systolic blood pressure (SMD: -0.20; 95% Cl: -5.23, 4.83; p = 0.938), diastolic blood pressure (SMD: -0.76; 95% Cl: -4.42, 2.91, p = 0.685), urine protein positive rate (SMD: 0.55; 95% Cl: 0.25, 1.22; p = 0.143) and ADR (SMD: 1.16; 95% Cl: 0.78, 1.72; p = 0.459). Conclusion: According to current study findings, topiroxostat may be useful for treating HUA and chronic renal disease in individuals, as evidenced by uric acid. However, topiroxostat did not significantly improve the levels of eGFR, BP and protein-positive rate of urine and the above conclusions need to be verified by more high-quality studies.

View Fulltext Back